Drug name | Country | Approval date | Indication |
---|---|---|---|
Docetaxel | US | N/A | N/A |
EU (EMA) [25] | Sept 2019 | In combination with ADT, with or without prednisone or prednisolone, are indicated for the treatment of patients with mHSPC | |
Japan | N/A | N/A | |
Abiraterone | Feb 2018 | In combination with prednisone for the treatment of high-risk patients with mHSPC | |
EU (EMA) [15] | Nov 2017 | In combination with prednisone or prednisolone for the treatment of newly diagnosed high risk mHSPC in adult men in combination with androgen deprivation therapy (ADT) | |
Japan (MHLW) [23] | Feb 2018 | For the treatment of hormone-naïve prostate cancer (HNPC) with high risk prognostic factors | |
Apalutamide | US (FDA) [19] | Sept 2019 | For the treatment of patients with mHSPC |
EU (EMA) [16] | Jan 2020 | Adult men with mHSPC in combination with ADT | |
Japan (MHLW) [24] | May 2020 | For the treatment of men with prostate cancer with distant metastases | |
Enzalutamide | US (FDA) [18] | Dec 2019 | For the treatment of patients with mHSPC |
EU (EMA) [21] | May 2021 | For the treatment of patients with mHSPC | |
Japan (MHLW) [20] | May 2020 | For the treatment of prostate cancer patients with distant metastasis |